Frontlight ResearchEarly access
Taking people in United StatesPhase 4
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 600 people, planned
- Started
- 18 Apr 2025
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- levetiracetam
- lacosamide
- Record updated
- 24 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- 18 years and older
- Diagnosis of traumatic brain injury: severe, moderate, or mild with high-risk imaging features
- Seizure prophylaxis with one of the two study drugs within 24 hours of initial injury
- Patients admitted into the trauma team service
Who cannot take part
- Enrolled in another interventional drug study
- Any active, witnessed, or unable to rule out seizure prior to prophylaxis initiation
- Received antiseizure medication (ASM), for prophylaxis or treatment, prior to randomization
- On anti-epileptic medications for seizures or indications other than seizures prior to admission
- Patient with a GCS of 15 or Legally Authorize Representative (LAR) unable to provide informed consent prior to randomization, or unable to read and understand English, Spanish, Vietnamese, Russian, Arabic, or French
- History of seizures
- Documented history of alcohol withdrawal and experiencing alcohol withdrawal on admission with initiation of clinical institute withdrawal assessment scale revised (CIWA-Ar) or modified Minnesota Detoxification Scale (mMINDS) requiring treatment
- History of bradycardia or permanent pacemaker or signs of bradycardia with HR < 55 bpm for > 5 min not on medications that cause bradycardia
- End-stage renal disease (ESRD)
- Spinal cord injury (SCI), confirmed by radiographic imaging demonstrating cervical (C1 to C8) or thoracic-spine (T1 to T12) injuries consistent with spinal cord injury
- Death, withdrawal of life support or transfer to hospice within 24 hours
- Pregnant or incarcerated
- Baseline GCS < 13 or unable to determine baseline GCS
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Bailey Baswell, BSTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with traumatic brain injury requiring seizure prophylaxis.
The 2 groups in the trial
- levetiracetamTreatment being tested
levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days
- lacosamideTreatment being tested
lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Seizure Prevention in Traumatic Brain Injury: A Comparative Effectiveness Study of Levetiracetam and Lacosamide
- Record updated
- 24 April 2026